BioDelivery (BDSI) Q3 Earnings Beat, Sales In Line, Stock Up
Zacks Investment Research | Nov 11, 2018 09:25PM ET
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) shares were up 2.4% on Nov 9 as earnings beat estimates and encouraging sales guidance. The company reported a loss of 10 cents per share for third-quarter 2018, which was narrower than the Zacks Consensus Estimate of a loss of 14 cents. In the year-ago quarter, the company had recorded a loss of 21 cents per share.
Shares of the company have gained 28.1% so far this year against the industry ’s 16.6% decrease.
Revenues increased 25.8% from the year-ago period and 16% sequentially. The increase in sales was mainly driven by strong demand for Belbuca. The top line was almost in line with the Zacks Consensus Estimate of $14 million.
The company reacquired worldwide rights to Belbuca in early 2017 from Endo International Plc (NASDAQ:ENDP) .
Quarter in Detail
BioDelivery’s chronic pain drug, Belbuca, continued its growth trend in the third quarter. The drug generated revenues of $12.4 million in the quarter, surging 92% year over year. Sales rose 27% sequentially.
During the quarter, the company recorded an all-time high in prescription volumes to almost 44,180 prescriptions for Belbuca. Prescription volume for Belbuca expanded 25% sequentially and 95% year over year. The strong growth was supported by improved preferred coverage with leading pharmacy benefit manager, Express Scripts (NASDAQ:ESRX) , adding the drug to its national preferred formulary list and expansion of sales force. The company has brought 100 million patients under preferred coverage so far this year, having started the year with 7 million.
The company added approximately 900 new patients to Belbuca treatment during the quarter, in-line with second-quarter 2018. Management seems confident about Belbuca’s continued strong performance in the fourth quarter of 2018.
Moreover, the settlement of the patent litigation with Teva Pharmaceuticals (NYSE:TEVA) in February will keep generic competition at bay till mid-2027.
Research and development expenses declined 64.8% from the year-ago period to $0.7 million. Selling, general and administrative expenses fell 9.3% year over year to $13.5 million in the quarter.
2018 Guidance
The company guided total revenues to be at the higher end of its previously issued range of $50 million to $52 million for 2018. The company also expects Belbuca sales at the higher end of previously estimated full-year sales outlook of $41 million-$43 million. In the third-quarter earnings release, the company stated that it anticipates total and Belbuca revenues to be toward the upper end of the guidance.
The Zacks Consensus Estimates for 2018 revenues stands at $53.18 million.
Get The News You Want
BioDelivery Sciences International, Inc. Price, Consensus and EPS Surprise
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.